Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis
Explore this paper's citation graph
Summary
The purpose of this review is to describe the risk factors associated with bleeding and thrombosis in MPN, as well as to review prevention strategies and management of these complications.
- Type
- review
- Published
- 2017-10-01
- Cited by
- 59
- References
- 59
- OpenAlex
- https://openalex.org/W2759822664
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3509532
Keywords
Medicine, Hematology, Thrombosis, Internal medicine, Intensive care medicine
References
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
- Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.
- Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.
- Thrombohemorrhagic complications of myeloproliferative disorders.
- Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
- Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients
- Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
- Cardiovascular events and intensity of treatment in polycythemia vera.
- Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
- Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort.
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
- Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.
- JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera
- Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.
- Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients
- Splanchnic vein thrombosis in myeloproliferative neoplasms
- Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
- Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain
Cited by
- The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia
- Pathogenetic mechanisms of thrombosis in patients with myeloproliferative neoplasm
- Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines—A Multidisciplinary (SEMI–SEOM–SETH) Expert Consensus
- Thromboembolic events in polycythemia vera
- No indication for CALR mutation analysis in Irish patients presenting with deep vein thrombosis or pulmonary embolism
- Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
- A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
- Thrombosis and Bleeding in Philadelphia Negative Myeloproliferative Neoplasia: Incidences and Risk Factors
- Severe acquired platelet dysfunction because of primary myelofibrosis with full functional and morphological recovery after allogeneic hematopoietic cell transplantation.
- Myeloid neoplasm with eosinophilia and ETV6-JAK2 fusion
- Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up
- Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria
- Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma
- Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults
- Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.
- Results of in vitro whole blood coagulation assays using ROTEM and the flow-chamber T-TAS system are affected by hematocrit.
- Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis
- Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature
- A Rare Association Between Prostate Cancer and Polycythemia Vera
- Frequency and characteristics of the JAK2 V617F mutation in 23 cerebral venous sinus thrombosis patients with thrombocytosis
Related papers
- DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION
- Genentech taps Affimed’s antibodies
- KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK
- Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria
- Cardiac retransplantation in children.
- Avaliacao hemodinamica sequencial em transplante de coracao
- Thoracoscopic discectomy and fusion in the treatment of spinal deformities
- [Hepatic retransplant and acute Budd Chiari syndrome. Case report].